ArticleJournal of neurology2021
The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression.
Article in Journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Global prevalence of fatigue in patients with multiple sclerosis: a systematic review and meta-analysis.Frontiers in neurology · 2024Pooled it
- Can Multiple Sclerosis be Managed Over a Lifetime? A Rare 72-Year Journey of Pediatric-Onset to Secondary Progressive Multiple Sclerosis.Clinical case reports · 2026Article
- Managing Relapsing Multiple Sclerosis Across the Lifespan: A Narrative Review with Expert Opinion from Norway.Neurology and therapy · 2026Review
- Differences in Income Growth Between People With Multiple Sclerosis and Controls: A Norwegian Cohort Study.European journal of neurology · 2026Article
- Longitudinal proteomic profiling of cerebrospinal fluid in untreated multiple sclerosis defines evolving disease biology.Nature communications · 2025Article
- The impact of changing diagnostic criteria on disability in a Brazilian multiple sclerosis cohort.Arquivos de neuro-psiquiatria · 2025Article
- Economic burden of secondary progressive multiple sclerosis: DISCOVER study.BMC health services research · 2025Observational
- Reduced childbirth rates in multiple sclerosis from the prodromal phase: Evidence from a population-based cohort study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Article
- The influence of menopause on multiple sclerosis.European journal of neurology · 2025Article
- Stable excess mortality in a multiple sclerosis cohort diagnosed 1970-2010.European journal of neurology · 2024Article
- Data-driven risk/benefit estimator for multiple sclerosis therapies.medRxiv : the preprint server for health sciences · 2024Article
- A comparison of multiple sclerosis disease characteristics across three genetically diverse Asian racial groups in Singapore.Scientific reports · 2024Observational
- Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study.Journal of neurology · 2024Article
- Longitudinal Optical Coherence Tomography Measurement of Retinal Ganglion Cell and Nerve Fiber Layer to Assess Benign Course in Multiple Sclerosis.Journal of clinical medicine · 2023Article
- Mapping the risk of infections in patients with multiple sclerosis: A multi-database study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data.Drug design, development and therapy · 2022Review
- Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population.Frontiers in neurology · 2022Article
- Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry.Frontiers in neurology · 2021Article
- Menopause and ageing in women with multiple sclerosis.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesOver the past few decades, there has been an improvement in the rate of disability progression in multiple sclerosis (MS) patients, and most studies relate this evolvement to the introduction of disease-modifying therapies. However, several other factors have changed over this period, including access to MRI and newer diagnostic criteria. The aim of this study is to investigate changes in the natural course of MS over time in a near-complete and geographically well-defined population from the south-east of Norway.
methodsWe examined disease progression and demographics over two decades and assessed the effect of disease-modifying therapies using linear mixed-effect models.
resultsIn a cohort of 2097 patients, we found a significant improvement in disability as measured by the Expanded Disability Status Scale (EDSS) stratified by age, and the improvement remained significant after adjusting for time on disease-modifying medications, gender and progressive MS at onset. The time from disease onset to EDSS 6 in the total cohort was 29.8 years (95% CI 28.5-31.1) and was significantly longer in patients diagnosed after 2006 compared to patients diagnosed before. There are significant differences between patient demographics, as well as time to EDSS 6, in the near-complete, geographically well-defined population compared to an additional cohort from the capital Oslo and its suburbs.
conclusionThe natural course of MS is improving, but the improvement seen in disease progression has multifaceted explanations. Our study underlines the importance of completeness of data, relevant timeframes and demographics when comparing different MS populations. Studies on incomplete populations should be interpreted with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.